高收入国家来源的脓毒症内型在撒哈拉以南非洲的真实世界纵向验证:一项巢式前瞻性多中心研究
该研究纳入马拉维和乌干达住院的临床疑似感染成人,对158名参与者的278份全血样本(第0、2/3、28天)进行RNA测序,脓毒症定义为mSOFA≥2。验证三种高收入国家来源的mRNA内型,发现SRS1、Mars2和炎症型内型与更差结局相关,30天死亡率风险比分别为2.81、3.11和2.66。纵向随访显示不良结局相关特征比例随时间下降,且内型分类与HIV状态无关。结论提示高收入国家鉴定的脓毒症内型在撒哈拉以南非洲具有相似的生物学和临床特征。
要点
- 在撒哈拉以南非洲住院脓毒症成人中,SRS1内型与30天死亡率升高相关(HR 2.81;95%CI 1.17–6.77)。
- Mars2内型与30天死亡率升高相关(HR 3.11;95%CI 1.24–7.79)。
- 炎症型(Inflammopathic)内型与30天死亡率升高相关(HR 2.66;95%CI 1.09–6.52)。
- 纵向随访显示不良结局相关特征比例下降、较轻特征比例上升,但可能存在幸存者偏倚。
- 内型分类与HIV状态无关(HIV血清阳性率51.3%)。
适用人群与场景
- 马拉维和乌干达住院的成人临床疑似感染患者,脓毒症定义为mSOFA≥2。
- 研究纳入158名参与者,HIV血清阳性率51.3%,脓毒症患病率56.3%。
诊断标准与关键阈值
- 脓毒症定义:改良序贯器官衰竭评估(mSOFA)评分≥2。
研究设计与关键结果
- 研究类型:巢式前瞻性多中心研究,隶属ARCS队列和CRISP研究;对158名参与者的278份全血样本(第0、2/3、28天)进行RNA测序。
- 最常见特征:SRS2(63.3%)、Mars3(31.2%)、凝血型(Coagulopathic,41.7%);最少见:SRS3(16.5%)、Mars4(12.7%)、适应型(Adaptive,27.7%)。
- 与其余内型合并相比,30天死亡率风险比:SRS1 HR 2.81(95%CI 1.17–6.77)、Mars2 HR 3.11(95%CI 1.24–7.79)、炎症型 HR 2.66(95%CI 1.09–6.52)。
- 随访样本显示不良结局相关特征比例下降、较轻特征比例上升,但可能存在幸存者偏倚。
- 疾病严重程度相似的内型间强相关(p<0.001;Cramer's V>0.4)。
- 内型分类与HIV状态无关。
证据类型、等级与局限
- 证据类型:巢式前瞻性多中心研究。
- 局限:原文报告可能存在幸存者偏倚。
对床旁实践的改变
- 作者认为高收入国家鉴定的脓毒症内型在撒哈拉以南非洲具有相似的生物学和临床特征。
- 作者指出需要评估这些内型在低收入和中等收入国家的适用性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Sub-Saharan Africa accounts for an estimated 40% of global sepsis-related deaths, with 30-day mortality exceeding 50% among hospitalized adults. While factors such as causative pathogens, comorbidities and delayed presentation contribute to mortality risk, the role of the host response remains poorly understood. In high income countries (HICs), transcriptomic endotypes have been linked to sepsis prognosis, highlighting distinct signatures. Assessing the applicability of these endotypes in low- and middle-income countries, particularly in sub-Saharan Africa where the sepsis burden is highest, is needed. METHODS: As part of the African Research Collaboration on Sepsis (ARCS) Cohort and the Cardiovascular Responses In Septic Patients (CRISP) studies, a subset of adult participants hospitalized with clinically suspected infection in Malawi and Uganda provided whole blood samples, collected longitudinally on days 0, 2/3 and 28, for RNA-sequencing. Sepsis was defined by a modified Sequential Organ Failure Assessment (mSOFA) score ≥ 2. Three sepsis messenger RNA endotypes [Sepsis Response Signature (SRS), Molecular Diagnosis and Risk Stratification of Sepsis (MARS) and Inflammopathic-Coagulopathic-Adaptive], previously derived in HIC settings, were validated for prognostic relevance among study participants. RESULTS: RNAseq was performed on a randomly selected subset of 278 samples belonging to 158 study participants, for whom HIV seropositivity was 51.3% and sepsis prevalence was 56.3% (mSOFA ≥ 2). The most commonly observed signatures over all timepoints were SRS2 (63.3%), Mars3 (31.2%) and Coagulopathic (41.7%), while SRS3 (16.5%), Mars4 (12.7%) and Adaptive (27.7%) were the least common. Participants classified as SRS1, Mars2 or Inflammopathic endotypes were associated with worse outcomes; when compared to the others pooled together, hazard ratios for 30-day mortality were significantly higher for the SRS1 (HR 2.81; 95% CI: 1.17–6.77), Mars2 (HR 3.11; 95% CI: 1.24–7.79) and Inflammopathic (HR 2.66; 95% CI: 1.09–6.52) signatures. Follow-up samples showed that the proportion of signatures associated with more adverse outcomes decreased, while the proportion of less severe ones increased, despite possible survivorship bias. Signatures associated with similar disease severity were strongly correlated between mRNA endotypes (p < 0.001; Cramer’s V > 0.4). Signature classification was not associated with HIV status. CONCLUSIONS: Sepsis endotypes identified in HICs exhibit similar biological and clinical characteristics in sub-Saharan Africa. Longitudinal analysis revealed that the proportion of adverse endotype signatures decrease over time.
参考来源
- Turgman O, Butler JM, Haguma P, et al. Real-world longitudinal validation of high-income-country-derived sepsis endotypes in sub-Saharan Africa: a nested prospective multicenter study. Crit Care. 2026. PMID: 41742286. doi:10.1186/s13054-026-05901-5
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。